Sangamo Biosciences (SGMO) AI Stock Analysis

• Market Cap: $158.76M
• Dividend Yield: N/A
• Average Volume (3M): 5.05M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.94
• Revenue Growth: -37.13%
• EPS Growth: 40.47%
• Country: US
• Employees: 183
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 336,494,480
• 10 Day Avg. Volume: 5,347,980
• 30 Day Avg. Volume: 5,050,939
• PEG Ratio: 0.03
• Price to Book (P/B): 9.04
• Price to Sales (P/S): 3.56
• P/FCF Ratio: -3.05
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $4.33
• Price Target Upside: 821.28% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -0.29
• Revenue Forecast (FY): $72.37M

• Rating: 45 Neutral
• Price Target: $0.50 ▲(6.38% Upside)

Sangamo Biosciences' overall stock score is primarily impacted by its poor financial performance and weak technical indicators. However, the positive developments from the earnings call, including clinical advancements and FDA endorsements, provide some optimism. The lack of attractive valuation metrics further weighs down the score.

Positive Factors

Clinical Advancements

The positive results from the STAAR study for Fabry disease indicate strong progress in Sangamo's clinical pipeline, potentially leading to accelerated FDA approval. This advancement strengthens Sangamo's position in the gene therapy market and could drive future revenue growth.

Pipeline Expansion

The initiation of the STAND study in chronic neuropathic pain marks Sangamo's expansion into neurology genomic medicine. This diversification enhances Sangamo's long-term growth prospects by broadening its therapeutic focus and addressing unmet medical needs.

Funding Strategy

The completion of an equity offering provides Sangamo with a financial runway into late 2025. This funding strategy supports ongoing R&D efforts and operational stability, allowing Sangamo to focus on strategic partnerships and clinical advancements.

Negative Factors

Financial Instability

Sangamo's declining revenue and negative cash flows highlight financial instability, posing risks to operational sustainability. This financial strain may limit Sangamo's ability to invest in R&D and necessitate additional funding, impacting long-term growth.

Balance Sheet Weakness

The significant decline in equity base reflects a weakened balance sheet, increasing financial leverage and risk. This deterioration may hinder Sangamo's ability to secure favorable financing terms and invest in strategic initiatives, affecting long-term viability.

Need for Additional Funding

Sangamo's reliance on securing additional funding and a commercialization partner for Fabry disease underscores financial challenges. This dependency could delay strategic initiatives and limit Sangamo's ability to capitalize on clinical advancements, affecting future growth.

Sangamo Biosciences Business Overview & Revenue Model

Company Description

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

How the Company Makes Money

Sangamo generates revenue through a combination of collaborations, licensing agreements, and funding from governmental grants and private investments. Key revenue streams include milestone payments and royalties from partnerships with major pharmaceutical companies, such as Pfizer and Biogen, in which Sangamo provides its gene editing technology for the development of novel therapies. Additionally, the company may receive upfront payments in collaboration agreements, as well as potential future earnings tied to the successful commercialization of partnered products. Sangamo also engages in research grants and funding opportunities to support its R&D efforts, further contributing to its overall revenue.

Sangamo Biosciences Financial Statement Overview

Summary

Sangamo Biosciences is facing significant financial challenges, including declining revenue and profitability, a weakening balance sheet with increased leverage, and persistent negative cash flows. These factors collectively indicate financial instability and increased operational risks.

Income Statement

Sangamo Biosciences has shown significant volatility in its revenue and profitability metrics. There has been a substantial decline in total revenue from $176.23M in 2023 to $57.8M in 2024, representing a negative revenue growth trend. Gross profit margins have been inconsistent, and the company consistently reports negative EBIT and net income margins, indicating ongoing operational and profitability challenges.

Balance Sheet

The balance sheet reflects a strained financial position with a declining equity base, from $82.89M in 2023 to $22.77M in 2024. The debt-to-equity ratio has worsened due to reduced equity, suggesting increased leverage. The equity ratio declined significantly, indicating reduced shareholder equity relative to total assets, potentially increasing financial risk.

Cash Flow

The cash flow statements highlight persistent negative free cash flow, with a slight improvement from -$246M in 2023 to -$67.4M in 2024. Operating cash flow has remained negative, raising concerns about the company's ability to generate cash from operations. The free cash flow to net income ratio remains unfavorable, reflecting poor cash conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	32.88M	57.80M	176.23M	111.30M	110.70M	118.19M
Gross Profit	32.29M	57.80M	176.23M	99.19M	110.70M	-62.45M
EBITDA	-105.17M	-89.09M	-96.80M	-189.17M	-165.70M	-123.87M
Net Income	-108.91M	-97.94M	-257.83M	-192.28M	-178.29M	-121.12M
Balance Sheet
Total Assets	88.64M	101.64M	165.32M	562.51M	721.92M	938.55M
Cash, Cash Equivalents and Short-Term Investments	29.62M	41.92M	81.00M	277.63M	376.55M	641.42M
Total Debt	25.42M	30.57M	38.10M	43.11M	48.08M	42.09M
Total Liabilities	82.40M	78.86M	82.43M	267.55M	346.58M	441.18M
Stockholders Equity	6.24M	22.77M	82.89M	294.96M	375.34M	498.23M
Cash Flow
Free Cash Flow	-76.40M	-67.41M	-246.00M	-243.80M	-256.53M	155.16M
Operating Cash Flow	-76.16M	-67.14M	-224.84M	-223.63M	-233.25M	169.88M
Investing Cash Flow	1.24M	37.52M	153.53M	59.28M	248.20M	-271.63M
Financing Cash Flow	62.94M	28.38M	14.59M	84.66M	32.86M	153.10M

Sangamo Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.47
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGMO, the sentiment is Negative. The current price of 0.47 is below the 20-day moving average (MA) of 0.61, below the 50-day MA of 0.60, and below the 200-day MA of 0.68, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 30.46 is Neutral, neither overbought nor oversold. The STOCH value of 18.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SGMO.

Sangamo Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CRBU	46 Neutral	$202.08M	-1.22	-68.93%	―	-72.45%	-28.60%
SGMO	45 Neutral	$158.76M	―	-480.02%	―	-37.13%	40.47%
APLT	39 Underperform	$145.45M	-2.27	-150.82%	―	―	―
CABA	39 Underperform	$233.24M	―	-76.34%	―	―	-41.69%
BDTX	33 Underperform	$226.60M	10.72	19.23%	―	―	―
ELTX	30 Underperform	$149.50M	-2.19	-9999.00%	―	―	-4.60%

Sangamo Biosciences Corporate Events

Sangamo Therapeutics Reports Q3 2025 Financial Results

Sangamo Therapeutics is a genomic medicine company focused on developing treatments for serious neurological diseases through innovative technologies like zinc finger epigenetic regulators and proprietary capsid discovery platforms. The company recently reported its third-quarter 2025 financial results, highlighting significant progress in its clinical and pre-clinical pipeline, including advancements in Fabry disease and chronic neuropathic pain studies.

Sangamo Biosciences Granted Nasdaq Compliance Extension

On October 29, 2025, Sangamo Therapeutics, Inc. received an extension from Nasdaq until April 27, 2026, to comply with the minimum bid price requirement of $1.00 per share for its continued listing on The Nasdaq Capital Market. This extension follows a previous notice on April 30, 2025, indicating non-compliance with the requirement. The company aims to meet the requirement by the deadline, but failure to do so may result in delisting, with the option to appeal the decision.

The most recent analyst rating on (SGMO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.

Sangamo Biosciences CFO Resigns, New Officer Appointed

Sangamo Therapeutics, Inc. announced the resignation of its Chief Financial Officer, Prathyusha Duraibabu, effective October 1, 2025. She will transition to part-time employment, continuing as the principal financial officer. In response, the company appointed Nikunj Jain as the principal accounting officer, effective the same date. Jain, who has been with the company since 2021, brings extensive experience from his previous roles at Coherus Biosciences and Deloitte & Touche LLP. The company has formalized employment agreements with both Jain and Duraibabu, outlining their compensation and benefits.

The most recent analyst rating on (SGMO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.

Sangamo Biosciences CFO Resignation Announced

On September 9, 2025, Prathyusha Duraibabu announced her resignation as Chief Financial Officer of Sangamo Therapeutics, effective October 1, 2025, to join a private AI company. Her departure is amicable and unrelated to any company disagreements. She will continue part-time to ensure continuity until a successor is appointed. The company acknowledges her significant contributions, particularly in strategic collaborations and investments, which have strengthened Sangamo’s position in the genomic medicines industry.

The most recent analyst rating on (SGMO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.

Sangamo Biosciences Reveals Promising Fabry Disease Study Results

On September 4, 2025, Sangamo Therapeutics announced updated clinical data from its Phase 1/2 STAAR study of isaralgagene civaparvovec, a gene therapy for Fabry disease, presented at ICIEM2025 in Kyoto. The study showed promising results, with patients demonstrating stable cardiac function and significant improvements in disease severity and quality of life. The company is preparing a Biologics License Application for accelerated approval, targeting submission in early 2026, contingent on securing additional funding. These developments could enhance Sangamo’s position in the gene therapy market and offer new treatment options for Fabry disease patients.

The most recent analyst rating on (SGMO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.

Sangamo Biosciences: Cautious Optimism in Earnings Call

Sangamo Biosciences recently held its earnings call, showcasing a cautiously optimistic outlook for the company’s future. The call highlighted significant advancements in their clinical pipeline, particularly in the Fabry disease program, which showed promising top-line results. However, the company’s future heavily relies on securing partnerships and funding, posing a financial risk. Overall, the sentiment expressed during the call was more positive than negative, with a focus on potential growth and innovation.

Sangamo Therapeutics Reports Strong Q2 2025 Results

Sangamo Therapeutics is a genomic medicine company focused on developing treatments for serious neurological diseases, utilizing its zinc finger epigenetic regulators and capsid discovery platform to address unmet medical needs. In its recent earnings report, Sangamo highlighted significant progress in its clinical programs, including positive results from its STAAR study for Fabry disease and the initiation of its STAND study for chronic neuropathic pain.